Treatment of tuberculosis in HIV infection

J. H. Grosset

Research output: Contribution to journalArticle

Abstract

Whether tuberculosis patients received short-course chemotherapy with treatment of isoniazid (INH) and rifampicin (RIF), combined or not with pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM), or long term chemotherapy with INH, SM and thiacetazone (Tb1), the rate of sputum culture conversion was similar in HIV-positive and HIV-negative patients. To prevent relapses it was recommended to treat patients for a minimum of 9 months and for at least 6 months after culture conversion, or even to administer INH for life after the end of treatment. However, no difference was observed in the percentage of relapses between HIV-positive and HIV-negative patients. Side-effects were observed in approximately 20% of HIV-positive patients treated with INH + RIF + PZA + EMB (or SM) or with INH + SM + Tb1, Tb1 being responsible for epidermal necrolysis, in some cases fatal. The mean survival of HIV-patients with tuberculosis was from 10 to 18 months after the diagnosis of tuberculosis. Other opportunistic infections could have been the main cause of death. Acquired drug resistance is not a common complication of tuberculosis treatment in HIV-positive patients, but several epidemics of nosocomial transmission of multiple drug-resistant tuberculosis have recently been observed in the USA. Sparfloxacin, a new fluoroquinolone with a long half-life and low MIC (0.25-0.50 mg/l) against Mycobacterium tuberculosis, is a promising drug against tuberculosis.

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalTubercle and Lung Disease
Volume73
Issue number6
StatePublished - Dec 1992
Externally publishedYes

Fingerprint

HIV Infections
Tuberculosis
HIV
Streptomycin
Pyrazinamide
Ethambutol
Rifampin
Therapeutics
Thioacetazone
Recurrence
Drug Therapy
Multidrug-Resistant Tuberculosis
Fluoroquinolones
Opportunistic Infections
Isoniazid
Sputum
Mycobacterium tuberculosis
Drug Resistance
Half-Life
Cause of Death

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology
  • Immunology

Cite this

Treatment of tuberculosis in HIV infection. / Grosset, J. H.

In: Tubercle and Lung Disease, Vol. 73, No. 6, 12.1992, p. 378-383.

Research output: Contribution to journalArticle

Grosset, JH 1992, 'Treatment of tuberculosis in HIV infection', Tubercle and Lung Disease, vol. 73, no. 6, pp. 378-383.
Grosset, J. H. / Treatment of tuberculosis in HIV infection. In: Tubercle and Lung Disease. 1992 ; Vol. 73, No. 6. pp. 378-383.
@article{0831dce282e248cca5c8f6be06bad861,
title = "Treatment of tuberculosis in HIV infection",
abstract = "Whether tuberculosis patients received short-course chemotherapy with treatment of isoniazid (INH) and rifampicin (RIF), combined or not with pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM), or long term chemotherapy with INH, SM and thiacetazone (Tb1), the rate of sputum culture conversion was similar in HIV-positive and HIV-negative patients. To prevent relapses it was recommended to treat patients for a minimum of 9 months and for at least 6 months after culture conversion, or even to administer INH for life after the end of treatment. However, no difference was observed in the percentage of relapses between HIV-positive and HIV-negative patients. Side-effects were observed in approximately 20{\%} of HIV-positive patients treated with INH + RIF + PZA + EMB (or SM) or with INH + SM + Tb1, Tb1 being responsible for epidermal necrolysis, in some cases fatal. The mean survival of HIV-patients with tuberculosis was from 10 to 18 months after the diagnosis of tuberculosis. Other opportunistic infections could have been the main cause of death. Acquired drug resistance is not a common complication of tuberculosis treatment in HIV-positive patients, but several epidemics of nosocomial transmission of multiple drug-resistant tuberculosis have recently been observed in the USA. Sparfloxacin, a new fluoroquinolone with a long half-life and low MIC (0.25-0.50 mg/l) against Mycobacterium tuberculosis, is a promising drug against tuberculosis.",
author = "Grosset, {J. H.}",
year = "1992",
month = "12",
language = "English (US)",
volume = "73",
pages = "378--383",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Treatment of tuberculosis in HIV infection

AU - Grosset, J. H.

PY - 1992/12

Y1 - 1992/12

N2 - Whether tuberculosis patients received short-course chemotherapy with treatment of isoniazid (INH) and rifampicin (RIF), combined or not with pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM), or long term chemotherapy with INH, SM and thiacetazone (Tb1), the rate of sputum culture conversion was similar in HIV-positive and HIV-negative patients. To prevent relapses it was recommended to treat patients for a minimum of 9 months and for at least 6 months after culture conversion, or even to administer INH for life after the end of treatment. However, no difference was observed in the percentage of relapses between HIV-positive and HIV-negative patients. Side-effects were observed in approximately 20% of HIV-positive patients treated with INH + RIF + PZA + EMB (or SM) or with INH + SM + Tb1, Tb1 being responsible for epidermal necrolysis, in some cases fatal. The mean survival of HIV-patients with tuberculosis was from 10 to 18 months after the diagnosis of tuberculosis. Other opportunistic infections could have been the main cause of death. Acquired drug resistance is not a common complication of tuberculosis treatment in HIV-positive patients, but several epidemics of nosocomial transmission of multiple drug-resistant tuberculosis have recently been observed in the USA. Sparfloxacin, a new fluoroquinolone with a long half-life and low MIC (0.25-0.50 mg/l) against Mycobacterium tuberculosis, is a promising drug against tuberculosis.

AB - Whether tuberculosis patients received short-course chemotherapy with treatment of isoniazid (INH) and rifampicin (RIF), combined or not with pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM), or long term chemotherapy with INH, SM and thiacetazone (Tb1), the rate of sputum culture conversion was similar in HIV-positive and HIV-negative patients. To prevent relapses it was recommended to treat patients for a minimum of 9 months and for at least 6 months after culture conversion, or even to administer INH for life after the end of treatment. However, no difference was observed in the percentage of relapses between HIV-positive and HIV-negative patients. Side-effects were observed in approximately 20% of HIV-positive patients treated with INH + RIF + PZA + EMB (or SM) or with INH + SM + Tb1, Tb1 being responsible for epidermal necrolysis, in some cases fatal. The mean survival of HIV-patients with tuberculosis was from 10 to 18 months after the diagnosis of tuberculosis. Other opportunistic infections could have been the main cause of death. Acquired drug resistance is not a common complication of tuberculosis treatment in HIV-positive patients, but several epidemics of nosocomial transmission of multiple drug-resistant tuberculosis have recently been observed in the USA. Sparfloxacin, a new fluoroquinolone with a long half-life and low MIC (0.25-0.50 mg/l) against Mycobacterium tuberculosis, is a promising drug against tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0027048452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027048452&partnerID=8YFLogxK

M3 - Article

C2 - 1337993

AN - SCOPUS:0027048452

VL - 73

SP - 378

EP - 383

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

IS - 6

ER -